Indivior Pharmaceuticals, Inc. (INDV) Free cash flow
- Free cash flow · 12 months (USD): Value $-111.00M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -8.34%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-111.00M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-40.00M − $71.00M ≈ $-111.00M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -8.34% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-111.00M ÷ $1.33B × 100 ≈ -8.34% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-40.00M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -0.11× | Operating cash flow / net income. Period ending 2026-06-30. $-40.00M ÷ $356.00M ≈ -0.11× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -40.00M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 71.00M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -111.00M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.33B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | |
| Net income | 356.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-111.00M | (m) | $-40.00M | $71.00M | (m) | $1.33B | (m) | $356.00M | (m) | (m) | -8.34% | -0.11× |
| 2026-03-31 | $-192.00M | (m) | $-111.00M | $81.00M | (m) | $1.29B | (m) | $252.00M | (m) | (m) | -14.88% | -0.44× |
| 2025-12-31 | $-93.00M | (m) | $-27.00M | $66.00M | (m) | $1.24B | (m) | $210.00M | (m) | (m) | -7.51% | -0.13× |
| 2025-09-30 | $119.00M | (m) | $177.00M | $58.00M | (m) | $1.18B | (m) | $129.00M | (m) | (m) | 10.08% | 1.37× |
| 2025-06-30 | $173.00M | (m) | $218.00M | $45.00M | (m) | $1.17B | (m) | $108.00M | (m) | (m) | 14.75% | 2.02× |
| 2025-03-31 | $116.00M | (m) | $148.00M | $32.00M | (m) | $1.17B | (m) | $-7.00M | (m) | (m) | 9.91% | -21.14× |
| 2024-12-31 | $7.00M | (m) | $36.00M | $29.00M | (m) | $1.19B | (m) | $2.00M | (m) | (m) | 0.59% | 18.00× |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-308.00M | (m) | $-300.00M | $8.00M | (m) | $1.09B | (m) | $-129.00M | (m) | (m) | -28.18% | 2.33× |
| 2022-12-31 | $-9.00M | (m) | $-4.00M | $5.00M | (m) | $901.00M | (m) | $-44.00M | (m) | (m) | -1.00% | 0.09× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |